Biome Australia Collaborates with FaBA to Develop BMB18 Probiotic

About Biome Australia Limited

Biome Australia Limited (ASX: BIO), founded in 2018 and headquartered in Australia, develops, licences, and markets innovative biotherapeutics, including probiotics and complementary medicines. The company partners with leading global microbiome research organisations to create clinically supported, evidence-based products. Biome operates both locally and internationally, distributing its products under the Activated Probiotics brand, which targets various health concerns such as mood regulation, gut health, and immune support. Currently, the company’s shares are trading at 62 cents per share.

Understanding the BMB18 Probiotic Strain

BMB18 is a unique strain of Lactobacillus plantarum, a beneficial bacterium commonly found in fermented foods and the human gut. This strain has demonstrated the potential to positively impact gut health by balancing the microbiome, which is essential for digestion and overall well-being. Early laboratory studies suggest that BMB18 may help strengthen the gut lining, reducing the likelihood of harmful substances passing into the bloodstream, which is a key factor in preventing inflammation and various digestive disorders.

Additionally, BMB18 has been shown to influence the immune system by promoting the growth of beneficial bacteria while suppressing harmful microorganisms. This balance can contribute to better digestion, reduced oxidative stress, and improved immune response. If further research confirms these findings, BMB18 could be a valuable natural solution for addressing gut-related conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Strategic Collaboration with FaBA

FaBA, led by The University of Queensland in collaboration with QUT, UniSQ, and UniQuest, fosters industry-university research partnerships to accelerate food and beverage innovation. This initiative helps bridge the gap between scientific discovery and commercial product development. By collaborating with FaBA, Biome gains access to world-class researchers, industry professionals, and advanced laboratory facilities that support the formulation and testing of BMB18 for potential market applications.

The partnership also aligns with Biome’s Vision 27 strategy, a long-term plan focused on scientific advancement, market expansion, and sustainability. Vision 27 aims to drive innovation by investing in high-quality clinical research, expanding Biome’s global footprint, and ensuring the development of sustainable and effective biotherapeutic products. By integrating this strategy into the collaboration with FaBA, Biome seeks to accelerate the commercialisation of innovative probiotic solutions, including BMB18, to improve consumer health and well-being.

Through this partnership, Biome and FaBA will work together to refine BMB18’s formulation, improve its effectiveness, and validate its health benefits through rigorous scientific research. This joint effort not only strengthens Biome’s probiotic research capabilities but also expands opportunities to integrate BMB18 into a variety of consumer products, including dietary supplements and functional foods designed to support digestive and immune health.

Financial and Intellectual Property Benefits

One of the most significant advantages of this partnership is Biome’s ability to fund research projects while maintaining complete ownership of any intellectual property generated. Under the agreement, Biome will approve all research projects and associated budgets, which will then be matched by FaBA’s federal government research grant. This funding model significantly reduces Biome’s financial burden while enabling the development of high-quality, scientifically validated probiotic solutions.

Additionally, the structure of this collaboration allows Biome to direct research efforts toward its long-term goals without external influence, ensuring that all innovations remain in the company’s control. By securing exclusive rights to the intellectual property of BMB18, Biome strengthens its competitive edge in the growing probiotic market.

Future Prospects and Industry Impact

This partnership represents a major milestone in Biome’s journey to becoming a leader in probiotic innovation. With access to FaBA’s extensive research network and financial backing, Biome is well-positioned to accelerate the development of BMB18 and expand its commercial reach.

As the company moves forward, its focus will be on conducting clinical trials to further validate BMB18’s benefits and exploring potential applications in various health and wellness products. The ultimate goal is to develop a scientifically proven probiotic solution that enhances gut health, supports the immune system, and improves overall quality of life.